首页 | 本学科首页   官方微博 | 高级检索  
     


FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
Authors:Lola Fashoyin-Aje  Martha Donoghue  Huanyu Chen  Kun He  Janaki Veeraraghavan  Kirsten B. Goldberg  Patricia Keegan  Amy E. McKee  Richard Pazdur
Affiliation:1. Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA;2. Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA;3. Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA;4. Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Abstract:
Keywords:GEJ adenocarcinoma  Accelerated approval  PD-L1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号